Hi Scott, I just looked at the last neuro drug David Stamler took to approval and acquisition. That was AUSTEDO, a drug which added an atom to a drug already in use for control of Huntington's movement problems. The AUSTEDO tweak resulted in the drug which was 3 times a day now to twice a day. Teva wanted it and paid over $3billion to acquire Auspex. 1st quarter earnings for AUSTEDO in the US were reported this year to be $282million. Up 67% over 1st quarter 2023.
Back to ATH. When they talk about a possible $1B market for ATH434, that is a pretty big deal for a $21million market cap co. Good results from the double blind early stage 201 clinical trial could put a smile on everybody's face when they see the price action following those results. All IMHO. Just need a good 201 trial result. I haven't been following this closely. Have you seen much evidence to expect a better result from 201 over the recent 202 interim results?
- Forums
- ASX - By Stock
- ATH
- Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-127
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $21.28M |
Open | High | Low | Value | Volume |
0.3¢ | 0.4¢ | 0.3¢ | $34 | 10K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
28 | 17196248 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 130790145 | 27 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
28 | 17196248 | 0.003 |
68 | 89903179 | 0.002 |
29 | 140710133 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 130790145 | 27 |
0.005 | 18848455 | 22 |
0.006 | 22089363 | 18 |
0.007 | 54073650 | 25 |
0.008 | 42418463 | 31 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
ATH (ASX) Chart |